BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11792410)

  • 21. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
    Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
    Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
    Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
    Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Long-term results with MACOP-B and radiation therapy for aggressive lymphomas].
    Krieger G; Kreysing E; Kneba M
    Onkologie; 2001 Feb; 24 Suppl 1():49-58. PubMed ID: 11441311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
    Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
    Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
    Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of mitoxantrone in non-Hodgkin's lymphoma.
    Armitage JO
    Oncology (Williston Park); 2002 Apr; 16(4):490-502, 507-8; discussion 511-2, 514. PubMed ID: 12017536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly.
    Fina M; Tani M; Stefoni V; Musuraca G; Marchi E; Pellegrini C; Alinari L; Derenzini E; Bacci F; Pileri S; Baccarani M; Zinzani PL
    Leuk Lymphoma; 2007 Nov; 48(11):2167-71. PubMed ID: 17990178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma].
    Hou M; Li L; Qiu M; Yan X; Zhu J; Gou HF
    Ai Zheng; 2005 Apr; 24(4):461-4. PubMed ID: 15820070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience.
    Kwak LW; Wilson M; Weiss LM; Doggett R; Dorfman RF; Warnke RA; Horning SJ
    J Clin Oncol; 1991 Aug; 9(8):1426-31. PubMed ID: 1712837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternating chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large-cell lymphoma: a single-institutional study with a long-term follow-up.
    Ohnoshi T; Hayashi K; Ueno K; Tada A; Mizuta J; Tagawa S; Matsutomo S; Saito S; Kawashima K; Yoshino T
    Int J Hematol; 1993 Aug; 58(1-2):93-8. PubMed ID: 7693030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of combination chemotherapy with cefoperazone on non-Hodgkin's lymphoma.
    Natazuka T; Matsui T; Ito M; Sugimoto T; Nakao Y; Fujita T
    Leuk Res; 1992; 16(4):417-8. PubMed ID: 1373460
    [No Abstract]   [Full Text] [Related]  

  • 33. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
    Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
    J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diffuse large-cell lymphoma of the testis.
    Tondini C; Ferreri AJ; Siracusano L; Valagussa P; Giardini R; Rampinelli I; Bonadonna G
    J Clin Oncol; 1999 Sep; 17(9):2854-8. PubMed ID: 10561362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
    Pfreundschuh M; Trümper L; Kloess M; Schmits R; Feller AC; Rudolph C; Reiser M; Hossfeld DK; Metzner B; Hasenclever D; Schmitz N; Glass B; Rübe C; Loeffler M;
    Blood; 2004 Aug; 104(3):626-33. PubMed ID: 14982884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
    Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma.
    Bertè R; Vallisa D; Civardi G; Moroni CF; Lazzaro A; Cavanna L
    Acta Haematol; 2001; 106(3):141-2. PubMed ID: 11713384
    [No Abstract]   [Full Text] [Related]  

  • 39. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
    Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
    Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.